[go: up one dir, main page]

MX2019007494A - Metodo para modular el crecimiento de celulas madre hematopoyeticas. - Google Patents

Metodo para modular el crecimiento de celulas madre hematopoyeticas.

Info

Publication number
MX2019007494A
MX2019007494A MX2019007494A MX2019007494A MX2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A
Authority
MX
Mexico
Prior art keywords
hsc
stem cell
hematopoietic stem
modulators
cell growth
Prior art date
Application number
MX2019007494A
Other languages
English (en)
Inventor
I Zon Leonard
E North Trista
GOESSLING Wolfran
Original Assignee
Children´S Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children´S Medical Center Corp filed Critical Children´S Medical Center Corp
Publication of MX2019007494A publication Critical patent/MX2019007494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención proporciona composiciones y métodos para modular poblaciones de células madre hematopoyéticas al utilizar moduladores de HSC, que son agentes que ya sea que incrementan los números de HSC o disminuyen los números de HSC como sea deseado por una indicación particular. Por ejemplo, los moduladores de HSC encontrados para incrementar los números de HSC incluyen prostaglandina E2 (PGE2) y agentes que estimulan la ruta de PGE2. A la inversa, los moduladores que previenen la síntesis de PGE2 disminuyen los números de HSC. Los moduladores de HSC pueden ser utilizados in vitro, in vivo o ex vivo.
MX2019007494A 2006-03-24 2008-09-23 Metodo para modular el crecimiento de celulas madre hematopoyeticas. MX2019007494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78596806P 2006-03-24 2006-03-24

Publications (1)

Publication Number Publication Date
MX2019007494A true MX2019007494A (es) 2019-09-06

Family

ID=38526581

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015007504A MX373998B (es) 2006-03-24 2007-03-26 Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc.
MX2008012178A MX2008012178A (es) 2006-03-24 2007-03-26 Metodo para modular el crecimiento de celulas madre hematopoyeticas.
MX2019007494A MX2019007494A (es) 2006-03-24 2008-09-23 Metodo para modular el crecimiento de celulas madre hematopoyeticas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2015007504A MX373998B (es) 2006-03-24 2007-03-26 Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc.
MX2008012178A MX2008012178A (es) 2006-03-24 2007-03-26 Metodo para modular el crecimiento de celulas madre hematopoyeticas.

Country Status (10)

Country Link
US (7) US8168428B2 (es)
EP (3) EP1999255A2 (es)
JP (8) JP5247675B2 (es)
CN (2) CN102626517B (es)
AU (1) AU2007230902B2 (es)
CA (1) CA2647201C (es)
MX (3) MX373998B (es)
RU (2) RU2493252C2 (es)
WO (1) WO2007112084A2 (es)
ZA (2) ZA200808123B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200808123B (en) * 2006-03-24 2010-03-31 Childrens Medical Center Method to modulate hematopoietic stem cell growth
RU2480213C2 (ru) 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Способ стимуляции регенерации тканей
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
JP5646990B2 (ja) 2007-04-23 2014-12-24 ストワーズ インスティテュート フォー メディカル リサーチ 幹細胞自己複製のための方法及び組成物
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
ITUD20080058A1 (it) 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
PT3031907T (pt) 2008-11-06 2021-01-28 Univ Indiana Res & Tech Corp Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP3533445A1 (en) * 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
WO2010121122A2 (en) * 2009-04-17 2010-10-21 The Brigham And Women's Hospital, Inc. Biomechanical induction of hematopoiesis
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
ES2727787T3 (es) 2009-11-15 2019-10-18 Univ Indiana Res & Tech Corp Métodos para mejorar el suministro y el injerto de células madre incluida la identificación de receptores específicos de prostaglandina E2
WO2011062584A1 (en) * 2009-11-19 2011-05-26 Regents Of The University Of Minnesota Reducing inflammation using cell therapy
EP2569412A4 (en) * 2010-05-10 2017-03-01 Fate Therapeutics, Inc. Biovessels
BR112013003366A2 (pt) * 2010-08-12 2020-08-04 Fate Therapeutics, Inc. terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras
PT2663313T (pt) * 2011-01-13 2018-10-23 Scipharm S A R L Método para melhorar o enxerto de células estaminais hematopoiéticas
WO2012149547A1 (en) 2011-04-28 2012-11-01 Duke University Methods of treating hemoglobinopathies
PT2760994T (pt) 2011-09-30 2017-08-24 Bluebird Bio Inc Compostos para melhor transdução viral
CA2857640C (en) 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2013086029A1 (en) 2011-12-05 2013-06-13 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
US9861685B2 (en) 2012-11-20 2018-01-09 Duke University Methods of treating hemoglobinopathies
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
WO2015164506A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
SG11201702134RA (en) 2014-09-16 2017-04-27 Sangamo Therapeutics Inc Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
CN107429230B (zh) 2015-01-26 2021-11-12 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
CN105296427A (zh) * 2015-10-23 2016-02-03 深圳爱生再生医学科技有限公司 造血干细胞的体外扩增培养方法
JP7189587B2 (ja) * 2015-10-30 2022-12-14 典正 三浦 メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
IL310683A (en) 2016-02-12 2024-04-01 Bluebird Bio Inc Vcn enhancer compositions and methods of using the same
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
EP4538365A3 (en) * 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3634425A4 (en) * 2017-06-07 2021-04-07 Academia Sinica METHOD OF ELIMINATION OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS
CA3065945A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US12215351B2 (en) 2017-08-22 2025-02-04 The Children's Medical Center Corporation Methods for inducing hematopoietic stem cell specificity
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3597211A1 (en) * 2018-07-19 2020-01-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Periostin compounds for the treatment of haematological complications
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
WO2020167948A1 (en) * 2019-02-13 2020-08-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for stem cell therapy
CN110051839A (zh) * 2019-04-16 2019-07-26 诺航生物技术(徐州)有限公司 一种促进脐带血干细胞体外扩增和增强脐带血干细胞移植后造血重建功能的药物
FI130749B1 (en) * 2020-01-24 2024-02-26 Faron Pharmaceuticals Oy USE OF VAP-1 INHIBITOR IN THE EX VIVO CULTURE OF HEMATOPOEITIC STEM CELLS AND IN THE TREATMENT OF BONE Marrow Loss or BONE Marrow Dysfunction
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11883436B2 (en) 2020-08-17 2024-01-30 The Board Of Trustees Of The University Of Illinois Method of preparing hematopoietic stem and progenitor cells for transplantation
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
KR20240136869A (ko) 2023-03-07 2024-09-19 인제대학교 산학협력단 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA103846A (en) 1906-12-03 1907-02-26 William Bell Manufacture of half-tone printing blocks
US3217903A (en) 1961-01-19 1965-11-16 Mc Graw Edison Co Segregating control
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4239679A (en) 1979-06-27 1980-12-16 Diamond Shamrock Corporation High bulk density rigid poly(vinyl chloride) resin powder composition and preparation thereof
HU181154B (en) 1980-07-18 1983-06-28 Epitestudomanyi Intezet Shaped building unit and space limiting or dividing structure made of same as well as method for producing the shaped building unit
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
EP0992579B1 (en) * 1989-10-16 2008-08-06 Amgen Inc. Stem cell factor
US5114672A (en) 1990-08-27 1992-05-19 Cryo-Cell International, Inc. Method for preserving blood fluid
WO1995006112A1 (en) * 1993-08-23 1995-03-02 Baxter International Inc. In vitro growth of neutrophil and megakaryocyte precursors in serum-free media
WO1996040866A1 (en) * 1995-06-07 1996-12-19 Novartis Ag Serum-free media for primitive hematopoietic cells and methods of use thereof
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
BR0015781A (pt) 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
US6226997B1 (en) 1999-12-07 2001-05-08 Cryo-Cell International, Inc. Method and device for maintaining temperature integrity of cryogenically preserved biological samples
US6852534B2 (en) 2000-11-03 2005-02-08 Kourion Therapeutics Gmbh Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
US20030032179A1 (en) 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom
JP4077158B2 (ja) 2001-01-10 2008-04-16 株式会社メニコン 植物性繊維分解剤およびそれを用いた植物性廃棄物の処理法
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
US8021876B2 (en) 2001-11-15 2011-09-20 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
AU2002350352A1 (en) * 2001-12-21 2003-07-15 Mount Sinai Hospital Cellular compositions and methods of making and using them
RU2205627C1 (ru) * 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
US7547715B2 (en) 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
MXPA05009398A (es) 2003-03-04 2005-12-05 Pfizer Prod Inc Uso de agonistas selectivos del receptor ep2 en tratamiento medico.
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
WO2004090121A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20080299095A1 (en) * 2004-07-09 2008-12-04 Bc Cancer Agency Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
US20090104159A1 (en) 2005-02-10 2009-04-23 Felipe Prosper Vascular/Lymphatic Endothelial Cells
US20080194024A1 (en) 2005-07-29 2008-08-14 Mays Robert W Culture of Non-Embryonic Cells at High Cell Density
JP4562618B2 (ja) 2005-08-18 2010-10-13 陽一 佐藤 空き缶処理車
AU2006326853B2 (en) * 2005-12-22 2012-02-16 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
ZA200808123B (en) 2006-03-24 2010-03-31 Childrens Medical Center Method to modulate hematopoietic stem cell growth
US8241903B2 (en) 2006-06-22 2012-08-14 Yeda Research And Development Co., Ltd. Catecholamine receptor modulation
WO2008021475A2 (en) 2006-08-16 2008-02-21 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
WO2008056963A1 (en) 2006-11-10 2008-05-15 Chanil Moon Method for proliferating stem cells with leptin
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
CA2647201C (en) 2016-03-08
US20090285786A1 (en) 2009-11-19
JP6041711B2 (ja) 2016-12-14
AU2007230902A8 (en) 2009-07-23
ZA200906574B (en) 2010-06-30
RU2011115827A (ru) 2012-10-27
RU2425876C2 (ru) 2011-08-10
JP2019214620A (ja) 2019-12-19
WO2007112084A9 (en) 2007-11-22
WO2007112084A8 (en) 2008-11-20
JP2015232010A (ja) 2015-12-24
JP2022025091A (ja) 2022-02-09
RU2008142106A (ru) 2010-04-27
MX373998B (es) 2020-07-22
JP6530732B2 (ja) 2019-06-12
US8168428B2 (en) 2012-05-01
US20130209424A1 (en) 2013-08-15
JP6208719B2 (ja) 2017-10-04
US8551782B2 (en) 2013-10-08
CN102626517B (zh) 2015-07-29
EP2423303A1 (en) 2012-02-29
JP6797222B2 (ja) 2020-12-09
JP2009530408A (ja) 2009-08-27
CA2647201A1 (en) 2007-10-04
US20120189593A1 (en) 2012-07-26
US20130209423A1 (en) 2013-08-15
HK1173948A1 (en) 2013-05-31
CN101495623B (zh) 2013-09-11
MX2008012178A (es) 2009-01-23
RU2493252C2 (ru) 2013-09-20
US10278990B2 (en) 2019-05-07
CN102626517A (zh) 2012-08-08
JP2013155175A (ja) 2013-08-15
CN101495623A (zh) 2009-07-29
WO2007112084A3 (en) 2009-01-08
EP3424507A1 (en) 2019-01-09
JP5247675B2 (ja) 2013-07-24
EP1999255A2 (en) 2008-12-10
AU2007230902A1 (en) 2007-10-04
JP2023112027A (ja) 2023-08-10
WO2007112084A2 (en) 2007-10-04
US20120189594A1 (en) 2012-07-26
US8563310B2 (en) 2013-10-22
ZA200808123B (en) 2010-03-31
US10272110B2 (en) 2019-04-30
US20130216507A1 (en) 2013-08-22
US9028811B2 (en) 2015-05-12
JP2016210802A (ja) 2016-12-15
AU2007230902B2 (en) 2013-03-14
US20120189592A1 (en) 2012-07-26
JP2019094347A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2019007494A (es) Metodo para modular el crecimiento de celulas madre hematopoyeticas.
GEP20146053B (en) Compounds expanding hematopoietic stem cells
UA103623C2 (ru) Регулятор роста растений
MX2009008019A (es) Uso de nanoparticulas carotenoides dispersibles en agua como moduladores de sabor, moduladores de sabor que contiene nanoparticulas carotenoides dispersibles en agua y metodo para modulacion de sabor.
MX2009004164A (es) Metodo para aumentar la regeneracion de tejido.
MA33955B1 (fr) Utilisation d'un métabolite naturel pour accroitre la production végétale.
MY159971A (en) Multipotent/pluripotent cells and methods
MY157445A (en) Compounds that modulate intracellular calcium.
EP4296270A3 (en) A composition comprising stem cell cultures
MX2009007266A (es) Formulaciones estables de acido s-(+)-abscisico liquidas y de granulo soluble.
MX345116B (es) Modulacion de bcl11a para tratamiento de hemoglobinopatias.
MX2010002712A (es) Compuestos que modulan calcio intracelular.
ECSP088854A (es) Moduladores bencimidazolicos de vr1
MX2008001614A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
ECSP099032A (es) Composiciones y métodos para la modulación del desarrollo vascular
WO2010129294A3 (en) Small molecules supporting pluripotent cell growth and methods thereof
TW200628428A (en) High calcium fertilizer composition
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
CR20130184A (es) Composiciones bioactivas de chromobacterium y metabolitos
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2009135905A3 (en) Mesenchymal stem cells and bone-forming cells
TW200942614A (en) Composition for modulating stem cell growth
SG148171A1 (en) Methods of proliferating stem cells
MY155410A (en) Compositions and devices